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Edited by Vladimir SkulachevAbstract Fluoxetine (Prozac) is a potent antidepressant com-
pound inhibiting serotonin reuptake, but also Na+, K+ and
Ca2+ channels and reported to both trigger and prevent apopto-
sis. Recently, ﬂuoxetine was found to increase the voltage sensi-
tivity of the mitochondrial voltage-dependent anion channel
(VDAC). VDAC which functions in transporting metabolites
across the mitochondria also plays a crucial role in apoptosis.
Here, we demonstrate that ﬂuoxetine interacted with VDAC
and decreased its conductance. Fluoxetine inhibited the opening
of the mitochondrial permeability transition pore, the release
of cytochrome c, and protected against staurosporine-induced
apoptotic cell death. These ﬁndings may explain some of the re-
ported ﬂuoxetine side eﬀects.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Fluoxetine, known also as Prozac, is a clinically used potent
antidepressant compound [1]. Fluoxetine is a selective seroto-
nin reuptake inhibitor with a high selectivity for the 5-
hydroxytryptamine (5-HT) transporter, and thus, in the brain,
modulates synaptic serotonin concentration [2]. However, ﬂu-
oxetine produces undesired side eﬀects including anxiety, sleep
disturbances, sexual dysfunction and gastrointestinal distur-
bances [3].
Besides the well-known action as serotonin reuptake inhibi-
tor, ﬂuoxetine exerts other eﬀects, such as blockade of muscu-
lar and neuronal nicotinic receptors [4] and inhibition of
monoamine oxidase A and B [5]. Fluoxetine has also been re-
ported to inhibit the activity of the voltage-dependent Na+ and
K+ and Ca2+ channels [6,7]. In addition, ﬂuoxetine inhibits the
multi-drug resistance extrusion pump and thus enhances the
response to chemotherapy. Indeed, ﬂuoxetine enhances doxo-
rubicin accumulation within tumors [8].
Several studies have linked ﬂuoxetine with cell proliferation
and an increased risk of developing cancer [9–11]. Fluoxetine
has been shown to enhance cell proliferation and to preventAbbreviations: PTP, permeability transition pore; STS, staurosporine;
VDAC, voltage-dependent anion channel
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[9] and inhibit UV-induced DNA fragmentation in U937 cells
[12]. Contradicting results showing enhancement of pro-
grammed cell death in various cell lines have also been re-
ported [13]. Fluoxetine was found to trigger rapid and
extensive apoptosis in Burkitt lymphoma cells that is prevented
by over-expression of the anti-apoptotic Bcl-2 [13].
Fluoxetine was shown to penetrate the cell membrane and to
be distributed in several intracellular compartments. 18F-Flu-
oxetine was found to bind mostly to mitochondria (60–70%),
but also to synaptosomes and other cellular organelles [14].
Recently, Thinnes [15] demonstrated that ﬂuoxetine in-
creases the voltage-dependence of the voltage-dependent anion
channel (VDAC1) incorporated into a planar lipid bilayer and
proposed that ﬂuoxetine blocks the mitochondrial permeabil-
ity transition pore (PTP). VDAC, also known as a mitochon-
drial porin, is a large channel that transports anions, cations,
[16,17] adenine nucleotides [18], Ca2+ [19] and other metabo-
lites [20] into and out of the mitochondrial intermembrane
space. VDAC also plays an important role in apoptosis by par-
ticipating in the release of intermembrane space proteins,
including cytochrome c [21].
In this study, we demonstrate that ﬂuoxetine-modiﬁed
VDAC conductance and prevented the opening of the mito-
chondrial PTP, release of cytochrome c and apoptotic cell
death induced by staurosporine (STS). The interaction of ﬂuox-
etine with the mitochondrial protein VDAC, inhibiting its
activity, may explain some of the clinically reported side eﬀects.2. Materials and methods
2.1. Materials
Tris, HEPES, asolactin, ﬂuoxetine, and Triton X-100 were
purchased from Sigma Chemicals Co., anti-VDAC antibody (Cal
Biochem) and HRP conjugated anti-mouse from Protos
Immunoresearch (San Francisco, CA). Hydroxyapatite (Bio-Gel
HTP) was purchased from Bio-Rad and Celite from the British Drug
Houses.
2.2. Mitochondrial preparation
Mitochondria were isolated from rat liver as described previously
[19] and used immediately.
2.3. Ca2+ accumulation
Freshly prepared mitochondria (1 mg/ml) were incubated at 30 C
for 2 min with ﬂuoxetine in the presence of 225 mM mannitol,
75 mM sucrose, 5 mM HEPES/KOH, pH 7.0, 5 mM succinate and
200 lM Pi. The reaction was initiated by the addition of 120 lMCaCl2
(containing 3 · 104 cpm/nmol 45Ca2+) and was terminated by rapid
Millipore ﬁltration followed by a wash with 5 ml of 0.15 M KCl.ation of European Biochemical Societies.
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Ca2+-induced mitochondrial swelling was assayed at 24 C and un-
der the same conditions as for Ca2+ accumulation. Swelling was initi-
ated by Ca2+ (200 lM) addition, and absorbance changes at 540 nm
were monitored with an Ultraspec 2100 spectrophotometer.
2.5. Release of cytochrome c
Mitochondria (1 mg/ml) were incubated with ﬂuoxetine for 2 min
and additional 15 min with Ca2+ (200 lM) in a solution containing
150 mM KCl, 25 mM NaHCO3, 5 mM succinate, 1 mM MgCl2,
3 mM KH2PO4, 20 mM HEPES, pH 7.4 [22]. Samples were centri-
fuged and the supernatants (40 ll) were subjected to sodium dodecyl
sulfate–polyacrylamide gel electrophoresis and Western blot analysis
using monoclonal anti-cytochrome c antibody (1:500) and HRP-conju-
gated anti-mouse IgG as a secondary antibody (1:10000).
2.6. Puriﬁcation of VDAC and single channel recording and analysis
VDAC was puriﬁed from rat liver mitochondria using LDAO and
hydroxyapatite followed by carboxymethyl (CM)-cellulose in which
LDAO was replaced by b-octylglucoside as previously described [16].
Reconstitution of puriﬁed VDAC into a planar lipid bilayer, single
channel current recording, and data analysis were carried out as previ-
ously described [19].3. Results
3.1. Fluoxetine interacts with VDAC to modify channel
conductance and voltage dependence
Puriﬁed VDAC (Fig. 1C), isolated from rat liver mitochon-
dria using CM-cellulose and b-octylglucoside, was reconsti-Fig. 1. Fluoxetine decreases VDAC channel conductance. (A) Puriﬁed VDA
through VDAC, in response to a voltage step from 0 to 10 mV or 0 to
ﬂuoxetine (50 lM). The dashed lines indicate the zero-current and the maxim
state conductance of VDAC before (d) and 10 min after the addition of
conductance was determined as the ratio of conductance at a given voltage (G
immunoblot (Ab) of puriﬁed VDAC used in these experiments.tuted into a planar lipid bilayer and its channel activity was
studied under voltage-clamp conditions. Current passing
through VDAC in response to voltages stepped from a holding
potential of 0 mV to 10 or 40 mV was recorded before and
after the addition of ﬂuoxetine (Fig. 1). At relatively small
membrane potentials (10 mV), the channel remained stable
in the full conducting state for over 30 min of recording. How-
ever, upon addition of ﬂuoxetine, the channel was stabilized in
its low-conducting state (Fig. 1A). At 40 mV, transitions be-
tween the main conductance state and the sub-conductance
state occurred and ﬂuoxetine stabilized the channel in the
low-conducting state (Fig. 1A). Fluoxetine-promoted VDAC
closure was observed at all voltages tested (Fig. 1B).3.2. Fluoxetine prevents PTP opening and release of cytochrome c
It has been suggested that activation of the Ca2+-dependent
mitochondrial PTP is a key event committing the cell to an
apoptotic fate [23]. PTP is a large channel proposed to be
formed by a direct association between VDAC in the OMM,
adenine nucleotide translocator, located in the IMM and
cyclophilin D in the matrix [16,23–26]. Since VDAC is a pro-
posed component of the PTP, the eﬀect of ﬂuoxetine on PTP
opening, as monitored by Ca2+ accumulation and swelling of
energized mitochondria, was examined.
When freshly isolated mitochondria were allowed to generate
a membrane potential, a transient Ca2+ accumulation was ob-
served; it reached a maximal level, and then rapidly releasedC was reconstituted into a planar lipid bilayer, and channel currents
40 mV, were recorded before and 5 or 10 min after the addition of
al current levels. (B) Multi-channel recordings of the average steady-
50 lM ﬂuoxetine (n) as a function of voltage are shown. Relative
) and the maximal conductance (G0). (C) Coomassie (CBB) staining and
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and suggests that mitochondria undergo a permeability transi-
tion, losing the accumulated Ca2+ via the PTP. The concentra-
tion dependence of ﬂuoxetine for preventing PTP opening was
examined at two time points – 1 and 4 min after initiating
Ca2+ accumulation (Fig. 2B). As expected, according to
Fig. 2A, after 1 min, Ca2+ content of the mitochondria was the
same in the absence or the presence of up to 50 lM ﬂuoxetine.
On the other hand, 4 min after initiation of Ca2+ accumulation,
in the absence of ﬂuoxetine, all accumulated Ca2+ was released.
This, however, was inhibited in the presence of ﬂuoxetine in a
concentration-dependent manner, with 50% and 100% inhibi-
tion of PTP opening obtained at about 18 and 50 lM, respec-
tively (Fig. 2B). The Ca2+ eﬄux mediated via activated PTP
and inhibited with ﬂuoxetine is also sensitive to the well-known
inhibitor of PTP, cyclosporin A (CsA) (Fig. 2C).
As shown in Fig. 3, in the presence of ﬂuoxetine, mitochon-
drial swelling, as monitored by the absorbance change follow-
ing Ca2+ addition, was inhibited by ﬂuoxetine (20 or 50 lM).
Fluoxetine inhibited PTP opening when added either prior to
PTP induction (Fig. 3A) or 1 min after initiation of Ca2+ accu-
mulation, but before PTP opening (Fig. 3B). As shown previ-
ously [23], this mitochondrial swelling is prevented by CsA
(Fig. 3A).Fig. 2. Fluoxetine inhibits mitochondrial PTP opening as monitored by relea
Ca2+ accumulation. (A) Ca2+ accumulation was assayed for the indicated ti
described in Section 2. (B) Mitochondria were assayed for Ca2+ accumulation
their Ca2+ content after 1 min (d) and 4 min (s) of incubation. Control activ
Ca2+ accumulation in the absence or the presence of 50 lM of ﬂuoxetine or
incubation.Thus, both swelling and Ca2+ accumulation, which reﬂect
PTP assembly or opening, are prevented by ﬂuoxetine.
Next, the eﬀect of ﬂuoxetine on the release of cytochrome c
from mitochondria was tested. Mitochondria were incubated
under conditions shown previously to activate cytochrome c
release [22]. In the presence of Ca2+ and succinate, cyto-
chrome c was released from mitochondria (as revealed by
Western blot analysis), where 20 and 50 lM of ﬂuoxetine
prevented 50% and 100%, respectively, of this release
(Fig. 3C).
3.3. Fluoxetine prevents STS-induced apoptotic cell death
Next we tested whether ﬂuoxetine, which prevented the re-
lease of cytochrome c (Fig. 3C), would suppress apoptosis
induced by STS in U-937 cells. Apoptotic cell death was in-
duced by exposure of control cells and cells incubated with
ﬂuoxetine (10, 20 or 50 lM) to STS (Fig. 4). Upon exposure
of control cells to STS for 5 h, about 70% of the cells under-
went apoptosis, whereas in cells not exposed to STS, 5% of
the cells died (Fig. 4A and B). When U-937 cells were incu-
bated with 50 lM ﬂuoxetine, a decrease of up to 80% in the
degree of STS-induced apoptotic cell death was observed
after 4–8 h incubation, and lower levels of protection were
obtained with 10 and 20 lM ﬂuoxetine (Fig. 4C).se of accumulated Ca2+. Mitochondrial PTP opening was followed by
me in the absence (d) and the presence (s) of 50 lM of ﬂuoxetine as
in the presence of diﬀerent concentrations of ﬂuoxetine and assayed for
ity (100%) was 68 nmol/mg protein. (C) Mitochondria were assayed for
10 lM CsA and assayed for their Ca2+ content after 2 and 5 min of
Fig. 3. Inhibition of PTP opening and cytochrome c release by ﬂuoxetine. (A) Ca2+-induced mitochondrial swelling was assayed in the absence (d)
or the presence of 5 lM (s), 10 lM (.) and 50 lM ﬂuoxetine (j) or 10 lM CsA (,). The absorbance changes at 540 nm were monitored for the
indicated time. (B) Mitochondria were exposed to swelling conditions and (where indicated by the second arrow) 5 lM (s) or 10 lM ﬂuoxetine (.)
was added 1 min after the addition of Ca2+ (indicated by the ﬁrst arrow). (C) Released cytochrome c was assayed using a monoclonal anti-
cytochrome c antibody, as described under Section 2.
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apoptosis when incubated with cells for 8 h at 20 lM or for
1 h at 50 lM (Fig. 4D).4. Discussion
In this study, we have characterized ﬂuoxetine modulation
of the mitochondrial phase of apoptosis using puriﬁed
VDAC, isolated mitochondria and tumor-derived cells in
culture. The results show that ﬂuoxetine: (a) interacted
directly with puriﬁed VDAC reconstituted into a planar lipid
bilayer to decrease channel conductance; (b) prevented PTP
opening as demonstrated by preventing the release of
accumulated Ca2+ and by swelling of energized mitochon-
dria; (c) inhibited release of cytochrome c from mitochon-
dria and (d) protected against STS-induced apoptotic cell
death. These results suggest that ﬂuoxetine interacts with a
mitochondrial component and prevents mitochondria-
mediated cell death. The speciﬁc protein(s) interacting with
ﬂuoxetine has not yet been identiﬁed. Accumulating evidence
suggests VDAC, located at the OMM is a key player in
apoptosis [19,26–29]. VDAC is a component of the PTP,
is involved in release of cytochrome c and regulates apopto-
tic cell death [26–29]. Fluoxetine interacting with VDAC and
modifying its conductance (Fig. 1), as well as inhibiting
mitochondrial PTP opening and release of cytochrome c
(Figs. 2 and 3) make VDAC an appropriate candidate for
a ﬂuoxetine target. Thus, the actions of ﬂuoxetine preventing
PTP opening and release of cytochrome c may result from
its interacting with VDAC and modifying its activity/confor-
mation. The eﬀect of ﬂuoxetine in delaying the onset of PTP
opening is similar to that of other PTP inhibitors such as
L-glutamate [30]. However, its eﬀect diﬀers from those
of CsA [23], RuR or Ru360 [19], hexokinase-I [22] orR068-3400 [24] which prevent PTP opening rather than
delaying it.
Recently [31], it has been proposed that plasma membrane
VDAC is involved in apoptotic cell death. Thus, the eﬀect
of ﬂuoxetine on cell death might result not only from its
interaction with mitochondrial VDAC, but also with plasma
membrane VDAC. Fluoxetine known as selective serotonin
reuptake inhibitor but it was found to possess a wide range
of biological activities such as interaction with Na+ and
K+ and Ca2+ channels [6,7]. In isolated mitochondria, ﬂuox-
etine indirectly aﬀects electron transport and (F1Fo)ATPase
activity, and thus inhibits oxidative phosphorylation, as a
result of interfering with the physical state of the lipid
bilayer of the inner mitochondrial membrane [32]. However,
these eﬀects of ﬂuoxetine on mitochondrial activities may
result from interacting with VDAC and decreasing its
conductance as a channel providing passage for Ca2+ [19],
adenine nucleotides [18] and other metabolites [20] into
and out of mitochondria [16]. The modiﬁcation of VDAC
conductance, and thereby of mitochondrial activities, may
explain some of the clinically reported side eﬀects for this
drug [3].
Recent epidemiological and laboratory studies have raised
questions regarding the association of antidepressant use
with cancer risk [33]. However, conﬂicting results of non-
association have been reported in a number of other studies
[34]. In vitro studies with tumor cells exposed to ﬂuoxetine
have shown inhibition [13] or stimulation [9,12] of cell
growth or DNA synthesis. Since alterations in cell prolifera-
tion, cell death or both lead to cancer development, the pos-
sible relation between inhibition of apoptotic cell death by
ﬂuoxetine and cancer requires further study. This includes
elucidating the mechanism by which ﬂuoxetine prevents
PTP opening and the release of the pro-apoptotic cyto-
chrome c, as well as clarifying the relationship between the
Fig. 4. Fluoxetine protects against apoptotic cell death induced by STS. (A) Human U-937 cells were incubated without (a,c) or with ﬂuoxetine
(20 lM) for 18 h (b,d) and were exposed to STS (1.25 lM) (c,d). After ﬁve hours cells were stained with acridine orange and ethidium bromide.
Arrows and arrowheads indicate cells in early and late apoptotic state, respectively. Scale bar, 20 lm. B–D present quantitative analysis of apoptotic
cell death. In B, quantitative analysis of apoptotic cell death was assessed 5 h after their exposure to STS (1.25 lM) by ANOVA and t-test. P < 0.001
was considered statistically signiﬁcant (***). Data are the means ± S.E.M, n = 3. In each independent experiment, approximately 200 cells were
counted. In C, U-937 cells were incubated with 10 lM (d), 20 lM (s) or 50 lM (m) of ﬂuoxetine for the indicated time and the degree of apoptotic
cells was analyzed. The results are presented as % of protection against STS-induced cell death. In D, cells were pre-incubated for 1 h (d) or 8 h (s)
with the indicated concentration of ﬂuoxetine and then apoptotic cell death was induced by 5 h incubation with STS.
E. Nahon et al. / FEBS Letters 579 (2005) 5105–5110 5109observed cancer-related eﬀects and ﬂuoxetine interaction
with mitochondria.
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